

Clinical trials of polypill for cardiovascular prevention in all type of patients

TrialResults-center www.trialresultscenter.org

1 polypill

Trial	Treatments	Patients	Trials design and methods
polypill vs error			
TIPS , 2009 [NCT00443794] n=NA follow-up: 3 months	Polycap versus Polycap components in eight formulations	subjects aged 45 to 80 years of age with at least one additional cardiovascular risk factor	Parallel groups double-blind
GAP ongoing [ACTRN12608000583347] n=NA follow-up:	Polypill in 2 versions one tablet taken orally per day for an average of 18 months versus usual care	people at high risk of cardiovascular disease	Parallel groups open
IMPACT ongoing [ACTRN12606000067572] n=600 follow-up: 12 months	polypill once a day versus usual care	subjects at high risk of cardiovascular disease in primary care	Parallel groups open New Zealand
high dose polypill vs low dose polypill			
TIPS 2 ongoing n=500 follow-up:	Polycap containing twice the amounts of the constituents, which represent the doses of the individual drugs that are proven to reduce clinical events versus low-dose Polycap	-	
polypill vs placebo			
NCT00603590 ongoing [NCT00603590] n=475 follow-up:	fixed-dose combination therapy with two antihypertensive drugs, aspirin and atorvastatin versus placebo	men aged 50 to 80 (inclusive) and women aged 55 to 80 (inclusive) who are currently not eligible for or taking antihypertensive or lipid lowering therapy	Parallel groups double-blind iran
polypill vs usual care			
UMPIRE ongoing [NCT01057537] n=NA follow-up:	fixed-dose, once-daily combination polypill, the Red Heart Pill versus Usual cardiovascular medications	-	Parallel groups Open
NCT00567307 ongoing [NCT00567307] n=200 follow-up:	Red Heart Pill 2b versus Usual Care	-	Parallel groups open Sri Lanka

References

TIPS, 2009:

Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. *Lancet* 2009 Apr 18;373:1341-51 [[19339045](#)] [10.1016/S0140-6736\(09\)60611-5](#)

Xavier D, Pais P, Sigamani A, Pogue J, Afzal R, Yusuf S The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. *Nat Clin Pract Cardiovasc Med* 2009;6:96-7 [[19104516](#)] [10.1038/ncpcardio1438](#)

GAP, :

IMPACT, :

TIPS 2, :

NCT00603590, :

Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"? *Arch Iran Med* 2008;11:306-13 [[18426322](#)] [08113/AIM.0012](#)

UMPIRE, :

NCT00567307, :

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.